Difference between revisions of "ALK translocation renal cell carcinoma"

From Libre Pathology
Jump to navigation Jump to search
Line 3: Line 3:
==General==
==General==
*Extremely rare - 1 in 829 consecutively screened patients.<ref name=pmid24255633>{{Cite journal  | last1 = Lee | first1 = C. | last2 = Park | first2 = JW. | last3 = Suh | first3 = JH. | last4 = Nam | first4 = KH. | last5 = Moon | first5 = KC. | title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. | journal = Korean J Pathol | volume = 47 | issue = 5 | pages = 452-7 | month = Oct | year = 2013 | doi = 10.4132/KoreanJPathol.2013.47.5.452 | PMID = 24255633 }}</ref>
*Extremely rare - 1 in 829 consecutively screened patients.<ref name=pmid24255633>{{Cite journal  | last1 = Lee | first1 = C. | last2 = Park | first2 = JW. | last3 = Suh | first3 = JH. | last4 = Nam | first4 = KH. | last5 = Moon | first5 = KC. | title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. | journal = Korean J Pathol | volume = 47 | issue = 5 | pages = 452-7 | month = Oct | year = 2013 | doi = 10.4132/KoreanJPathol.2013.47.5.452 | PMID = 24255633 }}</ref>
**In 2016, less than 17 cases reported.<ref name=pmid27554841>{{Cite journal  | last1 = Jeanneau | first1 = M. | last2 = Gregoire | first2 = V. | last3 = Desplechain | first3 = C. | last4 = Escande | first4 = F. | last5 = Tica | first5 = DP. | last6 = Aubert | first6 = S. | last7 = Leroy | first7 = X. | title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. | journal = Pathol Res Pract | volume = 212 | issue = 11 | pages = 1064-1066 | month = Nov | year = 2016 | doi = 10.1016/j.prp.2016.07.015 | PMID = 27554841 }}</ref>
*May be related to ''[[renal medullary carcinoma]]'' which is reported to have an ALK rearrangement - t(2;10)(p23;q22).<ref name=pmid21213368>{{Cite journal  | last1 = Mariño-Enríquez | first1 = A. | last2 = Ou | first2 = WB. | last3 = Weldon | first3 = CB. | last4 = Fletcher | first4 = JA. | last5 = Pérez-Atayde | first5 = AR. | title = ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. | journal = Genes Chromosomes Cancer | volume = 50 | issue = 3 | pages = 146-53 | month = Mar | year = 2011 | doi = 10.1002/gcc.20839 | PMID = 21213368 }}</ref>
*May be related to ''[[renal medullary carcinoma]]'' which is reported to have an ALK rearrangement - t(2;10)(p23;q22).<ref name=pmid21213368>{{Cite journal  | last1 = Mariño-Enríquez | first1 = A. | last2 = Ou | first2 = WB. | last3 = Weldon | first3 = CB. | last4 = Fletcher | first4 = JA. | last5 = Pérez-Atayde | first5 = AR. | title = ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. | journal = Genes Chromosomes Cancer | volume = 50 | issue = 3 | pages = 146-53 | month = Mar | year = 2011 | doi = 10.1002/gcc.20839 | PMID = 21213368 }}</ref>
*May respond to [[ALK inhibitors]] such as alectinib<ref name=pmid29685646>{{Cite journal  | last1 = Pal | first1 = SK. | last2 = Bergerot | first2 = P. | last3 = Dizman | first3 = N. | last4 = Bergerot | first4 = C. | last5 = Adashek | first5 = J. | last6 = Madison | first6 = R. | last7 = Chung | first7 = JH. | last8 = Ali | first8 = SM. | last9 = Jones | first9 = JO. | title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. | journal = Eur Urol | volume = 74 | issue = 1 | pages = 124-128 | month = 07 | year = 2018 | doi = 10.1016/j.eururo.2018.03.032 | PMID = 29685646 }}</ref> or crizotinib.<ref name=pmid27554841>{{Cite journal  | last1 = Jeanneau | first1 = M. | last2 = Gregoire | first2 = V. | last3 = Desplechain | first3 = C. | last4 = Escande | first4 = F. | last5 = Tica | first5 = DP. | last6 = Aubert | first6 = S. | last7 = Leroy | first7 = X. | title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. | journal = Pathol Res Pract | volume = 212 | issue = 11 | pages = 1064-1066 | month = Nov | year = 2016 | doi = 10.1016/j.prp.2016.07.015 | PMID = 27554841 }}</ref>
*May respond to [[ALK inhibitors]] such as alectinib<ref name=pmid29685646>{{Cite journal  | last1 = Pal | first1 = SK. | last2 = Bergerot | first2 = P. | last3 = Dizman | first3 = N. | last4 = Bergerot | first4 = C. | last5 = Adashek | first5 = J. | last6 = Madison | first6 = R. | last7 = Chung | first7 = JH. | last8 = Ali | first8 = SM. | last9 = Jones | first9 = JO. | title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. | journal = Eur Urol | volume = 74 | issue = 1 | pages = 124-128 | month = 07 | year = 2018 | doi = 10.1016/j.eururo.2018.03.032 | PMID = 29685646 }}</ref> or crizotinib.<ref name=pmid27554841>{{Cite journal  | last1 = Jeanneau | first1 = M. | last2 = Gregoire | first2 = V. | last3 = Desplechain | first3 = C. | last4 = Escande | first4 = F. | last5 = Tica | first5 = DP. | last6 = Aubert | first6 = S. | last7 = Leroy | first7 = X. | title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. | journal = Pathol Res Pract | volume = 212 | issue = 11 | pages = 1064-1066 | month = Nov | year = 2016 | doi = 10.1016/j.prp.2016.07.015 | PMID = 27554841 }}</ref>

Revision as of 14:13, 4 April 2019

ALK translocation renal cell carcinoma is a proposed entity within the Vancouver modification of the 2004 WHO classification of renal neoplasia.[1]

General

  • Extremely rare - 1 in 829 consecutively screened patients.[2]
    • In 2016, less than 17 cases reported.[3]
  • May be related to renal medullary carcinoma which is reported to have an ALK rearrangement - t(2;10)(p23;q22).[4]
  • May respond to ALK inhibitors such as alectinib[5] or crizotinib.[3]

Microscopic

Features:

DDx:

IHC

Features:[6]

See also

References

  1. Srigley, JR.; Delahunt, B.; Eble, JN.; Egevad, L.; Epstein, JI.; Grignon, D.; Hes, O.; Moch, H. et al. (Oct 2013). "The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.". Am J Surg Pathol 37 (10): 1469-89. doi:10.1097/PAS.0b013e318299f2d1. PMID 24025519.
  2. 2.0 2.1 Lee, C.; Park, JW.; Suh, JH.; Nam, KH.; Moon, KC. (Oct 2013). "ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients.". Korean J Pathol 47 (5): 452-7. doi:10.4132/KoreanJPathol.2013.47.5.452. PMID 24255633.
  3. 3.0 3.1 Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.
  4. Mariño-Enríquez, A.; Ou, WB.; Weldon, CB.; Fletcher, JA.; Pérez-Atayde, AR. (Mar 2011). "ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.". Genes Chromosomes Cancer 50 (3): 146-53. doi:10.1002/gcc.20839. PMID 21213368.
  5. Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.
  6. Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.